Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers

Integrated solution with self-service capabilities simplifies trial experience for all

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of clinical development and eCOA technology, today announced its next-generation digital oncology trial offering specifically designed to reduce operational complexity for sites and sponsors while meeting vulnerable cancer patients and their caregivers where they are with accessible, digital tools.

Oncology trials have historically been complicated but are becoming increasingly complex due to factors like advanced precision medicine, biomarker incorporation, and the need for broader patient populations, leading to challenges in trial design, recruitment, and data management. At the same time, the FDA is increasingly emphasizing electronic Patient-Reported Outcomes (ePROs) in oncology trials to systematically capture patient perspectives on symptoms, side effects, and quality of life through digital tools, which is changing how sponsors run cancer trials.

Medable’s newest oncology trial solution combines AI, automation, and differentiated eCOA capabilities to simplify oncology trials with real-time, high-quality patient data capture, remote participation, and continuous oversight. Medable’s solution streamlines workflows for sites, which are often managing multiple cancer studies, as well as sponsors and contract research organizations (CROs) that are building nuanced cancer trial protocols. As important, Medable puts patients at the center of the trial, making it easier to collect input directly from patients to turn their lived experiences into tangible data that drives cancer breakthroughs.

Medable’s digital trial platform is leveraged in global cancer trials across all four phases of research. The foundation of its oncology offering is AI-driven eCOA (including ePRO) technology. From data capture to real-time oversight, it enables the collection of high-quality patient data, including ePROs and digital measures, while supporting greater patient flexibility and delivering real-time oversight for a vulnerable population. Medable eCOA reduces patient burden – especially important in oncology, where protocol complexity is high and patients are often immunocompromised or fatigued – by digitizing assessments, shortening visit times, and enabling remote participation. It also includes protocol-ready libraries, rapid build capabilities, and site-friendly workflows that simplify execution and improve trial responsiveness.

“Medable’s digital trial platform is the engine that ensures every patient’s voice is heard,” said Musaddiq Khan, vice president of customer value and oncology lead at Medable. “It is specifically designed to address the biggest challenges in oncology trials, reducing complexity to speed processes with less burden on sites and greater clarity for researchers.”

Learn more at American Society of Clinical Oncology’s (ASCO) 2025 Annual Meeting (May 30-June 3) in Chicago at Medable Booth #10105.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.